Deep coma in a child treated with propranolol for infantile hemangioma

BACKGROUND: Propranolol hydrochloride is the first-line agent recommended for the treatment of infantile hemangiomas (IH). Serious adverse effects of propranolol therapy for hemangiomas are infrequent. CASE PRESENTATION: We report a case presented in deep hypoglycemic coma during his treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakalli, Ilirjana, Kola, Elmira, Lluka, Robert, Celaj, Ermela, Sala, Durim, Gjeta, Inva, Sallabanda, Sashenka, Klironomi, Dea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604368/
https://www.ncbi.nlm.nih.gov/pubmed/31266444
http://dx.doi.org/10.1186/s12887-019-1598-0
_version_ 1783431698616156160
author Bakalli, Ilirjana
Kola, Elmira
Lluka, Robert
Celaj, Ermela
Sala, Durim
Gjeta, Inva
Sallabanda, Sashenka
Klironomi, Dea
author_facet Bakalli, Ilirjana
Kola, Elmira
Lluka, Robert
Celaj, Ermela
Sala, Durim
Gjeta, Inva
Sallabanda, Sashenka
Klironomi, Dea
author_sort Bakalli, Ilirjana
collection PubMed
description BACKGROUND: Propranolol hydrochloride is the first-line agent recommended for the treatment of infantile hemangiomas (IH). Serious adverse effects of propranolol therapy for hemangiomas are infrequent. CASE PRESENTATION: We report a case presented in deep hypoglycemic coma during his treatment with propranolol for IH. Through our case report and the review of the literature, we aimed to underline the importance of recognizing adverse effects during propranolol therapy. Although propranolol has a long history of safe and effective use in infants and children, pediatricians should be aware that life-threatening adverse effects can happen during propranolol therapy for IH. CONCLUSION: Early identification of these adverse effects can be of great importance for patient management and prognosis. It must certainly be noted that not just early identification among doctors, but education for parents is crucial.
format Online
Article
Text
id pubmed-6604368
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66043682019-07-12 Deep coma in a child treated with propranolol for infantile hemangioma Bakalli, Ilirjana Kola, Elmira Lluka, Robert Celaj, Ermela Sala, Durim Gjeta, Inva Sallabanda, Sashenka Klironomi, Dea BMC Pediatr Case Report BACKGROUND: Propranolol hydrochloride is the first-line agent recommended for the treatment of infantile hemangiomas (IH). Serious adverse effects of propranolol therapy for hemangiomas are infrequent. CASE PRESENTATION: We report a case presented in deep hypoglycemic coma during his treatment with propranolol for IH. Through our case report and the review of the literature, we aimed to underline the importance of recognizing adverse effects during propranolol therapy. Although propranolol has a long history of safe and effective use in infants and children, pediatricians should be aware that life-threatening adverse effects can happen during propranolol therapy for IH. CONCLUSION: Early identification of these adverse effects can be of great importance for patient management and prognosis. It must certainly be noted that not just early identification among doctors, but education for parents is crucial. BioMed Central 2019-07-02 /pmc/articles/PMC6604368/ /pubmed/31266444 http://dx.doi.org/10.1186/s12887-019-1598-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Bakalli, Ilirjana
Kola, Elmira
Lluka, Robert
Celaj, Ermela
Sala, Durim
Gjeta, Inva
Sallabanda, Sashenka
Klironomi, Dea
Deep coma in a child treated with propranolol for infantile hemangioma
title Deep coma in a child treated with propranolol for infantile hemangioma
title_full Deep coma in a child treated with propranolol for infantile hemangioma
title_fullStr Deep coma in a child treated with propranolol for infantile hemangioma
title_full_unstemmed Deep coma in a child treated with propranolol for infantile hemangioma
title_short Deep coma in a child treated with propranolol for infantile hemangioma
title_sort deep coma in a child treated with propranolol for infantile hemangioma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604368/
https://www.ncbi.nlm.nih.gov/pubmed/31266444
http://dx.doi.org/10.1186/s12887-019-1598-0
work_keys_str_mv AT bakalliilirjana deepcomainachildtreatedwithpropranololforinfantilehemangioma
AT kolaelmira deepcomainachildtreatedwithpropranololforinfantilehemangioma
AT llukarobert deepcomainachildtreatedwithpropranololforinfantilehemangioma
AT celajermela deepcomainachildtreatedwithpropranololforinfantilehemangioma
AT saladurim deepcomainachildtreatedwithpropranololforinfantilehemangioma
AT gjetainva deepcomainachildtreatedwithpropranololforinfantilehemangioma
AT sallabandasashenka deepcomainachildtreatedwithpropranololforinfantilehemangioma
AT klironomidea deepcomainachildtreatedwithpropranololforinfantilehemangioma

Ejemplares similares